

Consolidated Financial Statements and Supplementary Information

December 31, 2024 and 2023

The Valley Hospital

Table of Contents
December 31, 2024 and 2023

	_ Page
Independent Auditors' Report	1
Consolidated Financial Statements	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	4
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7
Supplementary Information	
Consolidating Balance Sheet	26
Consolidating Statement of Operations and Changes in Net Assets	28



Independent Auditors' Report

To the Board of Trustees of The Valley Hospital

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of The Valley Hospital and affiliated companies (collectively, the Organization), which comprise the consolidated balance sheets as of December 31, 2024 and 2023, and the related consolidated statements of operations and changes in net assets and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, based on our audits and the reports of the other auditors, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Organization as of December 31, 2024 and 2023, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

We did not audit the financial statements of The Valley Medical Group, for which The Valley Hospital is the sole member, which statements reflect total assets constituting 9% and 7%, respectively, of consolidated total assets at December 31, 2024 and 2023, and total revenues constituting 18%, of consolidated total revenues for the years then ended. Those statements were audited by other auditors, whose report has been furnished to us, and our opinion, insofar as it relates to the amounts included for The Valley Medical Group, is based solely on the report of the other auditors.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern within one year after the date that the consolidated financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks.
 Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures
 that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
 effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings and certain internal control-related matters that we identified during the audit.

Report on Supplementary Information

Baker Tilly US, LLP

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary information included in the consolidating balance sheet as of December 31, 2024 and consolidating statement of operations and changes in net assets for the year then ended is presented for purposes of additional analysis rather than to present the financial position, results of operations and changes in net assets of the individual companies and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Iselin, New Jersey April 10, 2025

Consolidated Balance Sheets December 31, 2024 and 2023 (In Thousands)

	2024	20	023			2024	 2023
Assets				Liabilities and Net Assets			
Current Assets				Current Liabilities			
Cash and cash equivalents	\$ 16,086	\$	10,439	Accounts payable	\$	69,486	\$ 70,352
Assets whose use is limited, current	6,152		6,471	Accrued salaries and related benefits		77,491	72,356
Accounts receivable	157,201		126,113	Current portion of long-term debt		11,880	11,880
Prepaid expenses	9,468		11,507	Current portion of finance lease obligation		778	643
Supplies and other current assets	35,799		23,194	Current portion of operating lease liability		7,901	6,966
			_	Other accrued expenses		74,005	88,104
Total current assets	224,706		177,724	Accrued bond interest payable		6,152	 6,533
Assets Whose Use is Limited				Total current liabilities		247,693	256,834
Board designated	865,408		902,386			,000	_00,00.
Donor-restricted investments	6,797		6,776	Operating Lease Liability, Noncurrent Portion		147,643	92,793
	872,205	-	909,162	Long-Term Debt, Noncurrent Portion		306,352	321,382
Property and Equipment, Net	1,274,662	1,	,195,632	Finance Lease, Noncurrent Portion		56,831	57,610
Finance Lease Right-of-Use Asset	44,445		46,927	Estimated Professional Liability		35,049	36,445
Operating Lease Right-of-Use Asset	150,980		96,839	Amounts Due to Third-Party Payors			
				and Other Liabilities		79,999	88,941
Other Assets	85,668		81,782				
				Total liabilities		873,567	 854,005
Assets Held by Related Organization	33,543		28,948				
				Net Assets			
				Without donor restrictions		1,803,898	1,673,629
				With donor restrictions		8,744	 9,380
				Total net assets		1,812,642	1,683,009
Total assets	\$ 2,686,209	\$ 2	,537,014	Total liabilities and net assets	\$	2,686,209	\$ 2,537,014

Consolidated Statements of Operations and Changes in Net Assets Years Ended December 31, 2024 and 2023 (In Thousands)

		2024	2023
Changes in Net Assets Without Donor Restrictions			
Net patient service revenues	\$	1,286,148	\$ 1,173,858
Grant revenues and COVID-19 funding	·	12,573	29,536
Other revenues		60,986	48,613
Total operating revenues		1,359,707	1,252,007
Expenses			
Salaries and wages		574,135	514,047
Employee benefits		101,065	97,597
Medical fees		1,050	622
Other expenses		516,861	446,129
Interest expense		10,227	3,241
Depreciation		89,882	 53,464
Total operating expenses		1,293,220	 1,115,100
Operating income before other items and			
Operating income before other items and special projects		66,487	136,907
Other Items and Special Projects		(32,153)	 (36,570)
Operating income	\$	34,334	\$ 100,337

Consolidated Statements of Operations and Changes in Net Assets Years Ended December 31, 2024 and 2023 (In Thousands)

	2024		 2023
Other Income			
Income from operations	\$	34,334	\$ 100,337
Investment income		24,609	6,950
Change in unrealized gains on investments		44,720	73,522
Revenues in excess of expenses		103,663	180,809
Other Changes in Net Assets Without Donor Restrictions Net changes in assets held by related organization and			
net assets transfers to/from affiliated entities		26,606	19,774
Increase in net assets without donor restrictions		130,269	200,583
Changes in Net Assets With Donor Restrictions			
Decrease in assets with donor restrictions		(636)	 (470)
Increase in net assets		129,633	200,113
Net Assets, Beginning		1,683,009	 1,482,896
Net Assets, Ending	\$	1,812,642	\$ 1,683,009

Consolidated Statements of Cash Flows Years Ended December 31, 2024 and 2023 (In Thousands)

		2024		2023
Cash Flows From Operating Activities				
Increase in net assets	\$	129,633	\$	200,113
Adjustments to reconcile increase in net assets	*	,	*	
to net cash provided by operating activities:				
Depreciation		96,559		59,828
Finance lease right-to-use asset amortization		2,482		2,346
Operating lease right-to-use asset amortization		2,427		33,936
Amortization of bond premium, bond discount and deferred financing costs		(2,905)		(3,129)
Change in assets held by related organization		(4,595)		4,409
Net realized (gains) losses on investments		(2,406)		13,952
Change in unrealized (gains) losses on investments		(44,720)		(73,522)
Transfers to/from affiliated entities		(22,011)		(24,183)
Changes in assets and liabilities:				
Accounts receivable		(31,088)		(13,282)
Prepaid expenses, supplies and other current assets		(10,566)		(7,110)
Other assets		(3,886)		(13,058)
Accounts payable and other current liabilities		(10,211)		12,063
Medicare advance payments		-		-
Operating lease liabilities		(784)		(33,521)
Estimated professional liability		(1,396)		518
Amounts due to third-party payors and other liabilities		(8,942)		9,252
Net cash provided by operating activities		87,591		168,612
Cash Flows From Investing Activities		(4=======)		(0.45.550)
Purchase of property and equipment, including capitalized interest		(175,589)		(315,578)
Purchases of assets whose use is limited		(331,526)		(571,524)
Sales of assets whose use is limited		415,609		712,245
Net cash used in investing activities		(91,506)		(174,857)
Cash Flows From Financing Activities				
Transfers to/from affiliated entities		22,011		24,183
Principal payments on long-term debt		(12,125)		(17,290)
Principal payments on capital lease obligation		(643)		(515)
Net cash provided by financing activities		9,243		6,378
The cash provided by infairling addition		0,210		0,070
Increase in cash, cash equivalents				
and restricted cash and cash equivalents		5,328		133
Cash, Cash Equivalents and Restricted Cash and Cash Equivalents, Beginning		16,910		16,777
Cash, Cash Equivalents and Restricted Cash and Cash Equivalents, Ending	\$	22,238	\$	16,910
Supplemental Disclosure of Cash Flow Information				
Cash paid during the year for interest	\$	15,967	\$	16,752
Supplemental Schedule of Noncash Investing and Financing Activities				
Right-of-use assets obtained in exchange for lease obligations	\$	56,569	\$	55,584
Reconciliation of Cash, Cash Equivalents and Restricted Cash and Cash Equivalents to Balance Sheets				
Cash and cash equivalents, operations	\$	16,086	\$	10,439
Assets whose use is limited, current	Ψ	6,152	Ψ	6,471
		J, 102		٠, . ، ،
	\$	22,238	\$	16,910

Notes to Consolidated Financial Statements December 31, 2024 and 2023

1. Organization and Summary of Significant Accounting Policies

Organization

The Valley Hospital, Inc. (the Hospital) is a 370-bed, not-for-profit acute care hospital located in Paramus, New Jersey and is a subsidiary corporation of Valley Health System, Inc. (the System). The Hospital is a newly constructed facility which opened on April 14, 2024. This new facility replaces the old facility in Ridgewood, which will remain open and be repurposed.

The Hospital is the sole member of Valley Physician Services, Inc. (VPS). On January 1, 2017, VPS assigned its New Jersey physician contracts to Valley Physician Services, PC. Effective with the assignment of these contracts, VPS became a management services corporation providing service to both captive professional corporations: Valley Physician Services, P.C. and Valley Physician Services, NY, P.C.

All of VPS, Valley Physician Services, P.C. and Valley Physician Services NY, PC, trade under the name Valley Medical Group (VMG). All VMG operations are reflected in the 2024 and 2023 consolidated financial statements.

Other related corporations are Valley Home Care, Inc., The Valley Hospital Foundation, Inc. (the Foundation), VHS Insurance Company, LTD., ColigoCare, LLC (a clinically integrated network) and several limited liability corporations created for real estate acquisitions.

Principles of Consolidation

As of December 31, 2024 and 2023 and for the years then ended, the consolidated financial statements include the accounts of the Hospital and VMG and the other companies created for real estate acquisitions (collectively, the Organization). All significant intercompany accounts and transactions have been eliminated.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. There is at least a reasonable possibility that certain estimates will change by material amounts in the near term. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash and Cash Equivalents

The Organization considers all highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents, except for amounts reported within limited use assets. Cash and cash equivalents and restricted cash and cash equivalents include cash and money market funds. Restricted cash has been restricted by debt agreements for a specific purpose.

The Organization has balances in these financial institutions that exceed federal depository insurance limits. Management does not believe the credit risk related to these deposits to be significant.

Notes to Consolidated Financial Statements December 31, 2024 and 2023

Investments

All investments are classified as trading securities. Investments included in limited use assets in the accompanying consolidated balance sheets consist of cash and cash equivalents, equity securities, pooled equity funds, U.S. government obligations and government secured obligations, corporate bonds.

Investment income or loss (including realized gains and losses on investments, interest and dividends) and changes in unrealized gains and losses on investments are included in revenues in excess of expenses unless the income or loss is restricted by donor or law.

Investment income on deferred compensation investments and on other limited use assets is reported as other income in the consolidated statements of operations and changes in net assets. Deferred compensation assets are included in other assets on the consolidated balance sheets.

Assets Whose Use is Limited

Assets whose use is limited primarily include assets held by trustee under indenture agreements; designated assets set aside by the Board of Trustees (Board) for future capital improvements, over which the Board retains control and may at its discretion subsequently use for other purposes; and donor-restricted assets.

Accounts Receivable

Accounts receivable are recorded at net realizable value at the transaction price based on standard charges for services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured or underinsured patients in accordance with the Organization's policies and/or implicit price concessions provided to uninsured or underinsured patients and do not bear interest. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenues in the period of the change. Accounts are written off through the provision for credit loss when the Organization has exhausted all collection efforts and determines accounts are impaired based on changes in patient credit worthiness.

Supplies

Supplies are carried at the lower of cost (first-in, first-out method) or net realizable value. Supplies totaling approximately \$17.4 million and \$12.7 million are included in supplies and other current assets in the consolidated balance sheets at December 31, 2024 and 2023, respectively.

Property and Equipment

Property and equipment are recorded at cost. Annual provisions for depreciation of property and equipment are computed using the straight-line method. Additions are depreciated beginning with the month that the asset is placed in service.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such assets are deemed to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. There were no such impairment losses recorded in 2024 or 2023.

The Organization capitalizes interest costs as a component of construction in progress, based on interest costs of borrowing specifically for the project, net of interest earned on investments acquired with the proceeds of the borrowing.

Notes to Consolidated Financial Statements December 31, 2024 and 2023

Assets Held by Related Organizations

Accounting standards generally accepted in the United States of America establish guidelines for transactions in which an entity, the donor, makes a contribution by transferring assets to a not-for-profit organization or charitable trust, the recipient organization, that accepts the assets from the donor and agrees to use those assets on behalf of or transfer those assets, the return on those assets, or both, to another entity, the beneficiary, that is specified by the donor. The Organization recognizes its interest in the net assets of the Foundation and recognizes periodic changes in such interest in its consolidated statements of changes in net assets, as appropriate.

Donor-Restricted Gifts

Unconditional promises to give cash and other assets to the Organization are reported at fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the gift is received. The gifts are reported as support with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified as net assets without donor restrictions and reported in the consolidated statements of operations and changes in net assets as net assets released from restriction. Donor-restricted contributions whose restrictions are met within the same year as received are reported as contributions without donor restrictions in the accompanying consolidated financial statements.

Deferred Compensation

Certain Organization employees participate in deferred compensation plans. In connection with these plans, the Organization deposits amounts with trustees on behalf of the participating employees. The assets are restricted for payments under the plans, but may revert to the Organization in the event of a bankruptcy filing. At December 31, 2024 and 2023, amounts on deposit with trustees were equal to liabilities under the plans and aggregated \$10.1 million and \$13.4 million, respectively. Investments consist of mutual funds and are reported at fair value based upon quoted market price. Amounts on deposit are recorded in other assets and liability amounts are included in amounts due to third-party payors and other liabilities in the accompanying consolidated balance sheets.

The investments held by the trustees are classified as trading securities. For the years ended December 31, 2024 and 2023, the Organization recorded investment gains (losses) related to deferred compensation assets of \$1.6 million and \$1.9 million, respectively, as other revenues. Changes to the deferred compensation liability are recorded in employee benefits expense.

The Organization has a deferred compensation plan for certain executives which invests in life insurance policies for these executives. At December 31, 2024 and 2023, there is an insurance asset of \$24.8 million and \$24.0 million, respectively, which is included in other assets. Related benefit liabilities and expense of \$7.3 million and \$8.7 million in 2024 and 2023, respectively, are included in amounts due to third-party payors and other liabilities in the consolidated balance sheets and employee benefits expenses in the consolidated statements of operations and changes in net assets.

Deferred Financing Costs

Costs incurred in connection with the issuance of long-term debt have been deferred and are being amortized over the terms of the related debt using the effective interest method. Deferred financing costs are reported as a direct reduction of long-term debt.

Notes to Consolidated Financial Statements December 31, 2024 and 2023

Classification of Net Assets

The Organization separately accounts for and reports net assets with donor restrictions and net assets without donor restrictions. Net assets with donor restrictions are those whose use is restricted by the donor for a specified period of time or purpose or to be maintained by the Organization in perpetuity. The Organization recognizes its accumulated interest in the net assets of the Valley Hospital Foundation, Inc. (Foundation) as assets held by a related organization in the accompanying consolidated balance sheets. Changes in the Organization's interest in the net assets of the Foundation are reported in the accompanying consolidated statements of operations and changes in net assets. The net assets held by the Foundation on behalf of the Organization are for the benefit for the Organization for health care services and capital expenditures.

Self-Insured Health Benefits

The Organization maintains limited self-insured medical, dental and workers' compensation coverage for its employees. Claims under the plan are accrued as the incidents that give rise to them occur and an estimate of unpaid claims is included in other accrued expenses.

Medical Malpractice Insurance

The Organization participates in the VHS Insurance Company, LTD. (VHSIC) malpractice program. The provision for estimated medical malpractice claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported. The Organization records the actuarially determined liabilities for incurred but not reported professional and general liabilities. Anticipated insurance recoveries or claims receivable from VHSIC associated with reported claims are reported separately in the Organization's consolidated balance sheets at net realizable value in other assets.

Revenue Recognition

Net patient service revenues are recognized at the amount that reflects the consideration to which the Organization expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including commercial and governmental programs) and others and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, the Organization bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenues are recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Organization. Revenues for performance obligations satisfied over time is recognized based on actual services incurred in relation to total expected (or actual) payments. The Organization believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Organization receiving inpatient acute care services. The Organization measures the performance obligation from admission into the facility to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenues for performance obligations satisfied at a point in time are recognized when services are provided and the Organization does not believe it is required to provide additional services to the patient.

Generally, because all the Organization's performance obligations relate to contracts with a duration of less than one year, the Organization has elected to apply the optional exemption provided in Accounting Standard Codification (ASC) 606-10-50-14(a) and, therefore, the Organization is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Notes to Consolidated Financial Statements December 31, 2024 and 2023

The Organization determines the transaction price based on standard charges for services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Organization's policy and/or implicit price concessions provided to uninsured patients. The Organization determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. The Organization determines its estimate of implicit price concessions based on its historical collection experience with this class of patients.

Other Expenses

The major categories included in other expenses are drugs, surgical supplies, cardiac cath supplies, other medical supplies, professional fees, contracted services, rent, repairs and maintenance.

Measure of Operations

The consolidated statements of operations and changes in net assets reflect all operating revenues and expenses that are an integral part of the Organization's healthcare services and supporting activities and net assets released from donor restrictions to support operating expenditures. Changes in revenues in excess of expenses that are excluded from operating income, consistent with industry practice, include investment income (including realized and unrealized gains and losses on investments, interest, dividends and investment expense).

Revenues in Excess of Expenses

The consolidated statements of operations and changes in net assets include the determination of revenues in excess of expenses. Changes in net assets without donor restrictions which are excluded from the determination of revenues in excess of expenses, consistent with industry practice, include permanent transfers of assets to and from subsidiaries for other than goods and services and contributions of long-lived assets (including assets acquired using contributions which by donor restriction were to be used for the purposes of acquiring such assets).

Income Taxes

As of December 31, 2024 and 2023 and for the years then ended, the Hospital and VMG are not-for-profit corporations as described in Section 501(c)(3) of the Internal Revenue Code (IRC) and are exempt from federal income taxes on related income pursuant to Section 501(a) of the IRC.

The Organization accounts for uncertainty in income taxes by prescribing a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the tax uncertainty occurs if the recognition threshold has been met. There were no tax uncertainties that met the recognition threshold in 2024 or 2023.

Contract Balances

Contract assets represent the Organization's right to consideration in exchange for goods or services that the Organization has transferred to a patient/resident when that right is conditioned on something other than the passage of time (for example, the Organization's future performance). Contract liabilities represent the Organization's obligation to transfer goods or services to a resident for which the Organization has received consideration (or the amount is due) from the patient/resident.

The Organization's beginning and ending contract assets and liabilities are separately presented on the consolidated balance sheets as of December 31, 2024 and 2023. Contracts assets and liabilities as of December 31, 2022 are as follows:

Accounts Receivable
Estimated third-payor settlements

\$ 112,831 79.689

Notes to Consolidated Financial Statements December 31, 2024 and 2023

Subsequent Events

The Organization has evaluated the impact of subsequent events through April 10, 2025, representing the date at which the consolidated financial statements were issued.

2. Liquidity and Availability

The Organization's financial assets available within one year of the consolidated balance sheets date for general expenditure such as operating expenses are as follows (in thousands):

	2024		 2023
Financial assets at year-end:			
Cash and cash equivalents	\$	16,086	\$ 10,439
Accounts receivable		157,201	126,113
Board designated investments		865,408	 902,386
Total financial assets	\$	1,038,695	\$ 1,038,938

As part of the Organization's liquidity management, it has a policy to structure its financial assets to be available as its general expenditures, liabilities and other obligations come due. In addition, the Organization invests cash in excess of daily requirements in short-term investments.

3. Charity Care

The Organization provides care to patients who meet certain criteria defined by the New Jersey Department of Health (DOH) without charge or at amounts less than its established rates. Because the Organization does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue. Charges for charity care rendered were approximately \$23.5 million and \$29.9 million for the years ended December 31, 2024 and 2023, respectively. Total charity care costs were approximately \$6.1 million and \$7.2 million for the years ended December 31, 2024 and 2023, respectively.

Additionally, the Organization sponsors other charitable programs, which provide substantial benefit to the broader community. Such programs include services to the needy and elderly population that require special support, various clinical outreach programs, as well as health promotion and education for the general community welfare. Health care and other services are also provided to those covered by Medicaid and Medicare for which the Organization is not reimbursed at its full cost.

The Organization receives revenue through the State of New Jersey Charity Care Subsidy Fund. The amount received totaled \$0.3 million and \$0.7 million, respectively, for the years ended December 31, 2024 and 2023 and is included in other revenues.

4. Grant Revenues and COVID-19 Funding

Grant revenues and COVID-19 funding consist of amounts received from federal funding sources related to the COVID-19 pandemic and other State and Federal grants. The Organization accounts for this funding in accordance with the Financial Accounting Standards Board (FASB) ASC 958-605 guidance for conditional contributions and accordingly, revenues are recognized when barriers are substantially met, which occurs when the Organization complies with the terms and conditions related to the purpose of the grant rather than those that are administrative in nature. The Organization measures the amounts recognized in accordance with FASB ASC 606 for variable consideration, including constraints of variable consideration, and accordingly, revenue is measured at amounts for which it is probable that there will not be a significant reversal in a future period.

In 2024 and 2023, the Federal Emergency Management Agency (FEMA) obligated \$2.9 million and \$28.5 million, respectively, for COVID-19 emergency protective measures. The Organization accounted for such grants in accordance with Accounting Standards Update 2018-08 and considered to be conditional until the barriers of certain of the projects are overcome. During the years ended December 31, 2024 and 2023 grant amounts of \$2.9 million and \$28.5 million, respectively, were recognized as eligible costs were incurred and included in COVID-19 funding grant revenues in the accompanying consolidated statements of operations and changes in net assets.

In addition, the Organization received \$4.7 million and \$5 million in other State and Federal grant revenues, respectively for the year ended December 31, 2024.

5. Net Patient Service Revenues

The composition of the Organization's net patient care service revenues by payor for the years ended December 31 is as follows:

		2024		2023
Medicare	\$	333,766	\$	314,898
Horizon		260,666		254,866
United/Oxford		172,638		151,825
Self-pay/charity		7,885		9,196
Other		511,193		443,073
Total	<u></u> \$	1,286,148	\$	1,173,858

The composition of patient care service revenues based on the Organization's lines of business for years ended December 31 is as follows:

	2024		2023		
Hospital Physicians practice	\$	1,092,511 193,637	\$	998,315 175,543	
Total	\$	1,286,148	\$	1,173,858	

The Organization has agreements with third-party payors that provide for payment for services rendered at amounts different from its established rates. A summary of the payment arrangements with major third-party payors follows:

Medicare - The Organization is paid for most Medicare inpatient and outpatient services under the national prospective payment system and other methodologies of the Medicare program for certain other services. Federal regulations provide for certain adjustments to current and prior years' payment rates, based on industry-wide and hospital-specific data. Medicare cost reports of the Organization have been audited and settled for years through 2020 at December 31, 2024. Medicare informed hospitals of their intent to reopen cost report years 2006-2009 and 2011-2013. The Organization has filed appeals for 2010-2014 with the Provider Reimbursement Review Board.

Medicaid - Inpatient acute care services rendered to Medicaid program beneficiaries are paid at prospectively determined rates per discharge. Outpatient services rendered to Medicaid program beneficiaries are reimbursed under cost-based and fee schedule methodologies. The Organization is reimbursed for outpatient services at a tentative rate with final settlement determined after submission of annual cost reports and audits thereof by the Medicaid fiscal intermediary. The Medicaid cost reports of the Organization for years through 2021 have been audited and settled.

Other Third-Party Payors - The Organization also has entered into payment agreements with certain commercial insurance carriers and health maintenance organizations. The basis for payment to the Organization under these agreements includes prospectively determined rates per discharge or days of hospitalization and discounts from established charges.

Notes to Consolidated Financial Statements December 31, 2024 and 2023

There are various proposals at the federal and state levels that could, among other things, significantly reduce payment rates or modify payment methods. The ultimate outcome of these proposals and other market changes, including the potential effects of health care reform that has been enacted by the federal government, cannot presently be determined. Future changes in the Medicare and Medicaid programs and any reduction of funding could have an adverse impact on the Organization.

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. The Organization believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that could have a material adverse effect on its consolidated financial statements. Noncompliance with such laws and regulations could result in fines, penalties and exclusion from such programs.

Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Organization's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations. Revenues received under third-party arrangements are subject to audit and retroactive adjustments. There were no favorable transaction price adjustments related to successful settlements and favorable changes to estimated third-party payor settlement estimates in 2024 or 2023.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Organization also provides services to uninsured patients, and offers those uninsured or underinsured patients a discount, either by policy or law, from standard charges. The Organization estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charges by any contractual adjustment, discounts and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustment to net patient service revenues in the period of the change. For the years ended December 31, 2024 and 2023, the impact of changes in the estimates of discounts and contractual adjustments for performance obligations satisfied in prior years was insignificant to the consolidated financial statements.

Consistent with the Organization's mission, care is provided to patients regardless of their ability to pay. Therefore, the Organization has determined it has provided implicit price concessions to uninsured patients and other patient balances (for example, copays and deductibles). The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts the Organization expects to collect based on its collection history with those patients.

6. Assets Whose Use is Limited

The components of assets whose use is limited are set forth in the following table (in thousands):

	2024	 2023
Cash and cash equivalents Equity securities Pooled equity funds U.S. government obligations and government	\$ 42,150 48,659 247,247	\$ 31,212 37,422 192,960
secured obligations Corporate bonds Loomis Sayles mutual fund	 319,025 133,385 84,365	 422,032 147,950 80,029
	874,831	911,605
Accrued interest receivable	3,526	 4,028
Total	878,357	915,633
Less assets whose use is limited, current	6,152	 6,471
Assets whose use is limited, noncurrent portion	\$ 872,205	\$ 909,162

Unrealized gains and losses represent the change in the difference between cost and fair value of the limited use assets. For the years ended December 31, 2024 and 2023, the change in net unrealized gains was approximately \$44.7 million and \$73.5 million, respectively.

Investment income consists of the following (in thousands):

	 2024	 2023
Interest and dividend income Realized gains (losses) on sales of securities	\$ 22,203 2,406	\$ 20,902 (13,952)
Total investment income	\$ 24,609	\$ 6,950

7. Property and Equipment

A summary of property and equipment as follows (in thousands):

	 2024	 2023
Land Land improvements Building Equipment and furnishings	\$ 92,686 20,679 1,450,147 686,089	\$ 92,686 17,148 605,804 512,139
	2,249,601	1,227,777
Less accumulated depreciation	 1,013,674	 919,471
	1,235,927	308,306
Construction in progress	 38,735	 887,326
Property and equipment, net	\$ 1,274,662	\$ 1,195,632

Notes to Consolidated Financial Statements December 31, 2024 and 2023

Depreciation expense for the years ended December 31, 2024 and 2023 totaled \$96.6 million and \$59.8 million, respectively. Included in these amounts are \$6.7 million and \$6.4 million in 2024 and 2023, respectively, which are included in other items and special projects (see Note 12).

At December 31, 2024, the Organization had commitments outstanding of approximately \$16.5 million related to construction of The New Valley Hospital.

In 2024, the Organization began construction of a new Outpatient Care Center called the Montvale Market Square Ambulatory Center. There is a committed construction amount of \$22.1 million for the project.

8. Net Assets With Donor Restrictions

Net assets with donor restrictions are available for the following purposes (in thousands):

	;	2024	 2023
Health care services	\$	1,609	\$ 1,580
VMG services		1,947	2,604
Health education		759	767
Endowment funds		4,429	 4,429
Total	\$	8,744	\$ 9,380

Endowment funds have been restricted by donors to be maintained in perpetuity and are held by the Organization. The Organization follows the requirements of the Uniform Prudent Management of Institutional Funds Act (UPMIFA) as they relate to its donor-restricted contributions and net assets, effective upon the State of New Jersey's enactment of the legislation in March 2009.

The Organization has interpreted UPMIFA as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment fund absent explicit donor stipulations to the contrary. As a result of this interpretation, the Organization classifies as net assets with donor restrictions the original value of the gifts donated to the permanent endowment and the original value of subsequent gifts to the permanent endowment. Accumulations to the permanent endowment are used in accordance with the direction of the applicable donor gift. The remaining portion of the donor-restricted endowment fund that is classified as net assets with donor restrictions in perpetuity until the amounts are appropriated for expenditure in accordance with a manner consistent with the standard of prudence proscribed by UPMIFA. In accordance with UPMIFA, the Organization considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds: (1) the duration and preservation of the fund; (2) the purposes of the Organization and the donor-restricted endowment fund; (3) general economic conditions; (4) the possible effect of inflation and deflation; (5) the expected total return from income and the appreciation of investments; (6) other resources of the Organization; and (7) the investment and spending policies of the Organization.

The Organization has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to the endowment funds while seeking to maintain the purchasing power of the funds. To satisfy long-term return objectives, the Organization relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Organization employs a long-term equity oriented strategy of investing in both traditional and alternative asset classes.

9. Related-Party Transactions

The Organization has amounts due from related parties as follows (in thousands):

	 2024	 2023
Valley Health System, Inc. Valley Hospital Foundation, Inc.	\$ 7,494 837	\$ 776 938
Total	\$ 8,331	\$ 1,714

These amounts are reported within supplies and other current assets and primarily represent services provided and expenses paid on behalf of affiliates and are noninterest bearing.

The Organization had net asset transfers (to) and from related parties as follows (in thousands):

	 2024	2023
Contributions from Foundation	\$ 10,148	\$ 12,614
Change in assets held by related organization	5,252	(3,886)
Transfer from Hospital to VMG	(102, 186)	(99,811)
VMG net transfers	101,842	99,471
Transfer from Valley Health System	11,550	12,636
Acquisition companies net transfers	 -	 (1,250)
Total	\$ 26,606	\$ 19,774

These amounts are recorded as net changes in assets held by related organization and net transfers to/from affiliated entities on the consolidated statements of operations and changes in net assets. For the years ended December 31, 2024 and 2023, the Organization reported approximately \$10.1 million and \$12.6 million, respectively, of contributions received from the Foundation, which include both equipment reimbursements and other funds without donor restrictions. The Hospital and VMG reported \$33.5 million and \$28.9 million at December 31, 2024 and 2023, respectively, for its accumulated interest in Net Assets of the Foundation as assets held by related organization in the accompanying consolidated balance sheets. Changes in the Organization's interest in the net assets were \$5.3 million and \$(3.9) million for the years ended December 31, 2024 and 2023, respectively.

For the years ended December 31, 2024 and 2023, total costs, consisting of salaries and operating expenses of the Valley Health System, of \$117.7 million and \$109.5 million, respectively, were charged to individual entities based upon pre-determined allocation methods. These amounts are included in operating expenses on the consolidating statements of operations and changes in net assets.

10. Pension Plans

401(k) Retirement Savings Plan

In April 2004, the Organization introduced a 401(k) Retirement Savings Plan. All employees of the Organization who have attained the age of 21, completed one year of service and have at least 1,000 hours of service are eligible to participate. Employees may contribute 1% to 25% of their salary on a pretax basis, not to exceed the Internal Revenue Service limitation of \$23,000 in 2024 and \$22,500 in 2023. All employee pretax contributions are 100% vested. Prior to January 1, 2010, the Organization contributed 2% of the employee's base compensation and it matched up to 2% of the employee's contribution.

Effective January 1, 2010, the Organization introduced a new formula under the 401(k) plan to determine the basic contribution percentage that will be provided to each employee in the Organization. Using a points scale system, every employee will be credited with one point for each full year of credited service (a calendar year with 1,000 hours of service), as well as one point for each full year of employee's age. Basic contributions range from 1% to 6% based on points. Additionally, the Organization will match 100% of the first 3.5% employee contribution on top of the basic contribution.

Effective January 1, 2019, changes have been made to the basic and matching contributions. The basic contribution will now include only years of service and will range between 1.5% and 4%. Additionally, the Organization will match 100% of the first 1% employee contribution and 50% of the next 5% employee contribution on top of the basic contribution. The Organization contributed \$20.0 million and \$18.4 million to the 401(k) Retirement Savings Plan in 2024 and 2023, respectively.

11. Concentrations of Credit Risk

The Organization grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The concentrations of gross accounts receivable from patients and third-party payors were as follows:

	2024		2023	
Blue Cross	29	%	30 9	%
Medicare and Medicaid, including Managed Care	26		20	
Commercial	6		5	
United/Oxford	16		17	
Managed care	18		21	
Self-pay	5		7	
	100	%	100 9	%

12. Other Items and Special Projects

The components of other items and special projects are included in operating income, as follows (in thousands):

	 2024	2023
Offsite properties Strategic initiatives and other nonrecurring items	\$ (7,455) (24,698)	\$ (9,614) (26,956)
Total	\$ (32,153)	\$ (36,570)

13. Fair Value Measurements

For assets and liabilities required to be measured at fair value, the Organization measures fair value based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are applied based on the unit of account from the Organization's perspective. The unit of account determines what is being measured by reference to the level at which the asset or liability is aggregated (or disaggregated) for purposes of applying other accounting pronouncements.

Notes to Consolidated Financial Statements December 31, 2024 and 2023

The Organization follows a valuation hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2 - Observable inputs that are based on inputs not quoted in active markets, but corroborated by market data.

Level 3 - Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In determining fair value, the Organization uses valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers nonperformance risk in its assessment of fair value. Financial instruments (included in cash and cash equivalents, limited use assets and deferred compensation assets carried at fair value as of December 31, 2024 and 2023 are classified in the tables below in one of the three categories described above (in thousands):

	2024							
		_evel 1		Level 2	Lev	el 3		Total
Equity securities	\$	48,659	\$	-	\$	-	\$	48,659
Fixed income:								
Mortgage-backed securities		-		101,138		-		101,138
U.S. Treasuries		217,887		-		-		217,887
Corporate bonds		-		133,385		-		133,385
Loomis Sayles Mutual Fund Equity mutual funds:		84,365		-		-		84,365
Deferred Comp Mutual Funds		10,118		-		-		10,118
Pooled equity funds: MSCI ACWI EX-US								
Non-Lendable Fund Equity Index Non-Lendable		-		152,074		-		152,074
Fund		-		46,010		-		46,010
Russell 2000 Index Fund				49,163		-		49,163
Total assets in the fair								
value hierarchy	\$	361,029	\$	481,770	\$	-		842,799
Cash and cash equivalents								42,150
Assets at fair value							\$	884,949

The table above includes \$10,118 of deferred compensation mutual funds as of December 31, 2024 which are recorded to other assets on the consolidated balances sheets. The table above does not include \$3,526 of accrued investment income which is included in assets whose use is limited on the consolidated balance sheet.

	2023							
		_evel 1		Level 2	Leve	el 3	-	Total
Equity securities Fixed income:	\$	37,422	\$	-	\$	-	\$	37,422
Mortgage-backed securities		_		84,969		_		84,969
U.S. Treasuries		337,063		-		-		337,063
Corporate bonds		-		147,950		-		147,950
Loomis Sayles Mutual Fund Equity mutual funds:		80,029		-		-		80,029
Deferred Comp Mutual Funds Pooled equity funds: MSCI ACWI EX-US		13,372		-		-		13,372
Non-Lendable Fund Equity Index Non-Lendable		-		55,905		-		55,905
Fund		-		97,495		-		97,495
Russell 2000 Index Fund				39,560		-		39,560
Total assets in the fair	¢	467.006	Φ	405.070	ф			902 765
value hierarchy	<u> </u>	467,886	\$	425,879	\$			893,765
Cash and cash equivalents								31,212
Assets at fair value							\$	924,977

The table above includes \$13,372 of deferred compensation mutual funds as of December 31, 2023 which are recorded to other assets on the consolidated balances sheets. The table above does not include \$4,028 of accrued investment income which is included in assets whose use is limited on the consolidated balance sheet.

Financial Instruments

The following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in methodologies used at December 31, 2024 and 2023.

Equity securities: Valued at closing price reported on the active market on which the individual securities are traded.

Fixed income and equity mutual funds, U.S. government obligations, bonds and commercial mortgage-backed securities: Valued based on quoted market prices, estimated quoted market prices of similar securities and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.

The pooled equity funds are valued based on the underlying investments which are determined to have readily determinable fair value. The following represents the funds' objectives, restrictions and unfunded commitments:

Blackrock Equity Index Non-Lendable Fund: The fund's objective is to seek results that correspond to the price and yield performance of the S&P 500 Index. The Organization is required to provide notice for redemption of this fund by the 15th day of the month prior to redemption. There were no unfunded commitments related to this fund at December 31, 2024 and 2023.

Notes to Consolidated Financial Statements December 31, 2024 and 2023

Blackrock MSCI ACWI EX-US Non-Lendable Fund: The fund's objective is to seek investment results that correspond generally to the price and yield performance of the MSCI ACWI ex-U.S. Net Dividend Return Index. The Organization is required to provide notice for redemption of this fund by the 15th day of the month prior to redemption. There were no unfunded commitments related to this fund at December 31, 2024 and 2023.

Blackrock Russell 2000 Index Fund: The fund's objective is to seek investment results that correspond generally to the price and yield performance of the Russell 2000 Index. The Organization is required to provide notice for redemption of this fund by the 15th day of the month prior to redemption. There were no unfunded commitments related to this fund at December 31, 2024 and 2023.

14. Contingencies

Various investigations, lawsuits and claims arising in the normal course of operations are pending or on appeal against the Organization. While the ultimate effect of such actions cannot be determined at this time, it is the opinion of management that the liabilities which may arise from such actions would not materially affect the consolidated financial position or results of operations of the Organization.

15. Professional Insurance

Through March 20, 2003, the Organization had malpractice insurance coverage on a claims made basis under a retrospectively rated policy based primarily on experience of a group of health care providers. Premiums were accrued based on the ultimate cost of the Organization's claims experience to date. Losses from unasserted claims and incidents that may have occurred, but have not been identified under the incident reporting system are included in other accrued expenses in the amount of approximately \$1 million at December 31, 2024 and 2023 based principally on estimates that incorporate the Organization's past experience as well as other considerations, including the nature of each claim or incident and relevant trend factors.

Valley Health System., including The Valley Hospital Inc., Valley Physician Services, PC., trading as Valley Medical Group, Valley Home Care, Inc. and all other affiliates and subsidiaries, insure their Malpractice and general liability under a policy of insurance from VHS Insurance Company, Ltd. VHS Insurance Company, Ltd. Is an insurance company in the Cayman Islands and is 100% owned by Valley Health System. Under this policy of insurance, each entity, as applicable, has a Captive retention of \$10.0 million per claim not to exceed \$20.0 million in the aggregate, and \$2.0 million combined single limit for any one claim event or General Liability injury.

The actuarially determined undiscounted professional and general liabilities aggregated approximately \$35.0 million and \$36.4 million at December 31, 2024 and 2023, respectively (includes approximately \$9.6 million and \$8.8 million at December 31, 2024 and 2023, respectively, for estimated incurred but not reported costs) and are reported as estimated professional liability in the Organization's consolidated balance sheets. At December 31, 2024 and 2023, approximately \$50.2 million and \$43.8 million, respectively, of assets held by the captive for insurance claims, are included in other assets in the accompanying consolidated balance sheets.

The Organization maintains excess liability coverage with several qualified commercial carriers of up to \$40 million loss per incident once in excess of primary coverage.

Notes to Consolidated Financial Statements December 31, 2024 and 2023

16. Other Revenues

The Organization's other revenues consist of the following (in thousands):

	 2024	2023
Patient Education	\$ 336	\$ 382
Valley Health Pharmacy	22,104	16,670
Food services	3,218	2,296
Purchase discounts and rebates	14,477	11,681
Investment income (loss)	2,419	2,692
Charity care subsidy	258	661
Acquisition companies rent	4,133	3,831
ColigoCare shared savings	4,400	3,749
Other	 9,641	 6,651
Total	\$ 60,986	\$ 48,613

17. Right-of-Use Assets and Lease Liabilities

The Organization enters into finance and operating leases for buildings, office space and equipment. As of January 1, 2019, the Organization adopted the provisions of ASC 842. Accordingly, all agreements with terms for more than one year were capitalized, where a right-of-use asset was identified. In connection with the adoption of ASC 842 on January 1, 2019, certain practical expedients available under ASC 842-10-65-1 were elected that provide certain concessions to ease the burden of transition, such as the treatment of indirect lease costs, and service contracts which may contain embedded leases. In addition, certain expedients not related to the transition were elected, such as the election to capitalize lease and nonlease components of an agreement as a single component for purposes of simplicity, with the exception of those related to equipment and machinery. Generally, amounts capitalized represent the present value of minimum lease payments over the term, and the duration is equivalent to the base agreement, however, management used certain assumptions when determining the value and duration of leases. These assumptions include, but are not limited to, the probability of renewing a lease term, certain future events impacting lease payments, as well as fair value not explicit in an agreement. Most of our leases do not include variable payments but contain scheduled escalations. The leases expire at various dates through 2047.

Operating Right-of-Use Assets and Operating Lease Liabilities

In the calculation of the right-of-use asset and lease liability, the Organization assumed lease renewals of one to three terms where it was probable that the Organization would continue to utilize the facility. Lease expense is recognized on a straight-line basis over the lease term and is included in other expenses on the consolidated statements of operations and changes in net assets. Lease expense was approximately \$13.6 million and \$11.8 million for the years ended December 31, 2024 and 2023, respectively. The Organization had a current lease liability of approximately \$7.9 million and \$7.0 million at December 31, 2024 and 2023, respectively, and a noncurrent lease liability of approximately \$147.6 million and \$92.8 million at December 31, 2024 and 2023, respectively. The future lease payments are discounted using the practical expedient for not-for-profit entities, which is the risk-free interest rate. The interest rate used in calculating the lease liability ranges from 0.27% to 3.04% depending on the length of the lease term. Additional information with respect to the Organization's operating leases as of December 31, 2024 and 2023 is presented below.

Weighted	Average	Discount

	Rat	е
	2024	2023
Hospital	1.82 %	1.50 %
VMĠ	3.65	3.04

Weighted Average Remaining Lease Term in Years

	2024	2023
Hospital	4.05	4.29
VMĠ	18.20	14.90

The following table presents information about the amount and timing of cash flows arising from operating leases as of December 31, 2024 (in thousands):

2025	\$ 13,173
2026	12,465
2027 2028	12,367 11,840
2029	11,242
Thereafter	122,202
Total lease payments	183,289
Less interest	(27,745)
Present value of lease liabilities	\$ 155,544

Finance Lease Right-of-Use Asset and Finance Lease Obligation

On October 12, 2016, the Organization entered into leasing arrangement by which the lessor will construct a fitness and wellness center with medical office space and ancillary service facilities which was made available for use by the Organization upon substantial completion of construction of the leased premises. The lease commencement date, the date the leased premises is made available for use to the Organization, was February 1, 2018. The lease is payable in monthly installments over a period of 25 years from the lease commencement date with a purchase option of \$1 at the end of the term.

The lease was recorded as a finance lease with a long-term lease asset and lease liability in the amount of approximately \$59.7 million and is amortized over the term of the lease. The following is a schedule by years of future minimum lease payments under the finance lease as of December 31, 2024 (in thousands):

2025	\$ 3,816
2026	3,921
2027	4,029
2028	4,140
2029	4,254
Thereafter	 77,208
Total minimum lease payments	97,368
Less amount representing interest at 6%	 (39,759)
Present value of net minimum lease payments	\$ 57,609

Notes to Consolidated Financial Statements December 31, 2024 and 2023

18. Long-Term Debt

In December 2019, the Hospital completed a financing (Series 2019) with the New Jersey Health Care Facilities Financing Authority (NJHCFFA) for \$356,410,000 of publicly issued tax-exempt bonds. These funds, together with investment earnings and other available funds, will be used to finance the costs of planning, development, acquisition, construction, equipping, expansion, furnishing and renovation of a new 370 bed, approximately 875,000 square foot acute care hospital and medical center facility located in Paramus, New Jersey, including a 1,500 space parking garage attached thereto, and all infrastructure improvements, relocations and modifications.

The Series 2019 funds are structured with fixed-rate serial bonds maturing from 2020 to 2039 and fixed-rate term bonds maturing in 2044 and 2049.

Yields on the Series 2019 serial bonds range from 1.12% for the 2020 maturity to 2.56% for the 2039 maturity. Yields for the fixed-rate term bonds are as follows: for the term bond maturing in 2044, a yield to call of 2.71% and for the term bond maturing in 2049, a yield to call of 3.15%.

The overall interest cost for the bond issue is 2.93%. During 2024 and 2023, \$2.5 million and \$10.3 million, respectively, of interest costs incurred with the new hospital were capitalized and included within construction in progress in the consolidated financial statements.

A summary of long-term debt is as follows as of December 31, 2024 and 2023 (in thousands):

	 2024	2023		
Hospital revenue bonds financed with the NJHCFFA,				
Series 2019	\$ 291,345	\$	303,470	
Net original issue premium	46,027		46,027	
Less current portion	(11,880)		(11,880)	
Less unamortized underwriter discount	(1,168)		(1,268)	
Less accumulated amortization of bond premium	(17,350)		(14,303)	
Less unamortized bond issuance costs	 (622)		(664)	
Long-term debt	\$ 306,352	\$	321,382	

Principal payments for the next five years under the NJHCFFA obligations are as follows (in thousands):

2025	\$ 11,880
2026	11,880
2027	11,880
2028	11,880
2029	11,880
Aggregate thereafter	 231,945
	\$ 291,345

The 2019 Bonds loan agreements require the Hospital to comply with financial covenants.

In 2023, the Hospital began an initiative to Repurchase Valley Hospital Bonds back from the Bond Holders. In total, the Hospital purchased back a total Par Value of \$5.7 million in Bonds, for a total proceeds of \$4.4 million.

Notes to Consolidated Financial Statements December 31, 2024 and 2023

19. Functional Expenses

The consolidated financial statements report certain categories of expenses that are attributed to more than one program or supporting function. Therefore, expenses require allocation on a reasonable basis that is consistently applied. Salaries, benefits, medical fees and other expenses are allocated based upon estimates of time and effort. Depreciation and interest are allocated based upon square footage. Amounts shown are in thousands:

	2024									
	 Total		Program	Administrative						
Salaries and wages Employee benefits Medical fees Other expenses Depreciation Interest	\$ 574,135 101,065 1,050 516,861 89,882 10,227	\$	494,310 85,349 1,050 413,751 68,000 10,227	\$	79,825 15,716 - 103,110 21,882					
Total	\$ 1,293,220	\$	1,072,687	\$	220,533					
	 Total		Program	Administrative						
Salaries and wages Employee benefits Medical fees Other expenses Depreciation Interest	\$ 514,047 97,597 622 446,129 53,464 3,241	\$	444,344 82,577 622 354,981 38,710 3,241	\$	69,703 15,020 - 91,148 14,754					
Total	\$ 1,115,100	\$	924,475	\$	190,625					

The Valley Hospital
Consolidating Balance Sheet
December 31, 2024 (In Thousands)

	Valley Hospital	Valley Medical Group	Real Estate Acquisition Companies	Eliminations	Consolidated
Assets					
Current Assets					
Cash and cash equivalents	\$ 12,254	\$ 2,247	\$ 1,585	\$ -	\$ 16,086
Assets whose use is limited, current	6,152	-	-	-	6,152
Accounts receivable	140,492	16,709	-	-	157,201
Prepaid expenses	9,245	223	-	-	9,468
Supplies and other current assets	29,773	6,026			35,799
Total current assets	197,916	25,205	1,585		224,706
Assets Whose Use is Limited					
Board designated	865,408	-	-	-	865,408
Donor-restricted investments	6,797				6,797
	872,205				872,205
Property and Equipment, Net	1,194,729	56,186	23,747	-	1,274,662
Finance Lease Right-of-Use Asset	44,445	-	-	-	44,445
Operating Lease Right-of-Use Assets	1,568	149,412	-	-	150,980
Other Assets	85,310	12	346	-	85,668
Assets Held by Related Organization	31,596	1,947			33,543
Total assets	\$ 2,427,769	\$ 232,762	\$ 25,678	\$ -	\$ 2,686,209

The Valley Hospital
Consolidating Balance Sheet
December 31, 2024
(In Thousands)

Liabilities and Net Assets	Valley Hospital	Valley Medical Group	Real Estate Acquisition Companies	Eliminations	Consolidated
Current Liabilities					
Accounts payable	\$ 65,881	\$ 3,605	\$ -	\$ -	\$ 69,486
Accrued salaries and related benefits	59,552	17,939	-	-	77,491
Current portion of long-term debt	11,880	-	-	-	11,880
Current portion of finance lease obligation	778	-	-	-	778
Current portion of operating lease liability	689	7,212	-	-	7,901
Other accrued expenses	52,023	21,981	1	-	74,005
Accrued bond interest payable	6,152			<u> </u>	6,152
Total current liabilities	196,955	50,737	1	-	247,693
Operating Lease Noncurrent Portion	879	146,764	-	-	147,643
Long-Term Debt, Noncurrent Portion	306,352	-	-	-	306,352
Finance Lease, Noncurrent Portion	56,831	-	-	-	56,831
Estimated Professional Liability	35,049	-	-	-	35,049
Amounts Due to Third-Party Payors and Other Liabilities	68,754	11,245			79,999
Total liabilities	664,820	208,746	1		873,567
Net Assets					
Without donor restrictions	1,756,152	22,069	25,677	-	1,803,898
With donor restrictions	6,797	1,947			8,744
Total net assets	1,762,949	24,016	25,677		1,812,642
Total liabilities and net assets	\$ 2,427,769	\$ 232,762	\$ 25,678	\$ -	\$ 2,686,209

The Valley Hospital
Consolidating Statement of Operations and Changes in Net Assets
Year Ended December 31, 2024
(In Thousands)

	 Valley Valley Medical Hospital Group			Real Estate Acquisition Companies		1		Co	onsolidated	
Changes in Net Assets Without Donor Restrictions Net patient service revenues Grant revenues Other revenues	\$ 1,092,511 12,573 47,586	\$	193,637 - 48,123	\$	- - 4,133	\$	- - (38,856)	\$	1,286,148 12,573 60,986	
Total operating revenues	 1,152,670		241,760		4,133		(38,856)		1,359,707	
Expenses Salaries and wages Employee benefits Medical fees Other expenses Interest expense Depreciation	361,831 69,444 39,906 420,728 10,227 82,793		212,304 31,621 - 93,232 - 7,089		- - - 2,901 -		- (38,856) - - -		574,135 101,065 1,050 516,861 10,227 89,882	
Total operating expenses	984,929		344,246		2,901		(38,856)		1,293,220	
Operating income (loss) before other items and special projects	167,741		(102,486)		1,232		-		66,487	
Other Items and Special Projects	 (30,884)				(1,269)		-		(32,153)	
Operating income (loss)	136,857		(102,486)		(37)		-		34,334	
Other Income (Loss) Nonoperating gains and losses Change in unrealized gains on investments	 24,609 44,720		- -		<u>-</u>		<u>-</u>		24,609 44,720	
Revenues in excess of (less than) expenses	206,186		(102,486)		(37)				103,663	
Other Changes in Net Assets Without Donor Restrictions Net changes in assets held by related organization and net assets transfers to/from affiliated entities	(75,237)		101,843		<u>-</u>				26,606	
Total other changes in net assets without donor restrictions	 (75,237)		101,843						26,606	
Increase (decrease) in net assets without donor restrictions	 130,949		(643)		(37)				130,269	
Increase (decrease) in net assets without donor restrictions	 130,949		(643)		(37)				130,269	
Changes in Net Assets With Donor Restrictions Net assets released from restriction for operating purposes	21		(657)						(636)	
Increase (decrease) in net assets with donor restrictions	 21		(657)						(636)	
Increase (decrease) in net assets	130,970		(1,300)		(37)		-		129,633	
Net Assets, Beginning	 1,631,979	_	25,316		25,714				1,683,009	
Net Assets, Ending	\$ 1,762,949	\$	24,016	\$	25,677	\$		\$	1,812,642	